The literature for this narrative review was identified through a comprehensive search of the electronic databases PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library for relevant articles published between January 2000 and June 2025. The search strategy employed a combination of keywords and Medical Subject Headings (MeSH) terms related to the core concepts (“curcumin” OR “diferuloylmethane” OR “turmeric”) AND (“oral health” OR “periodontitis” OR “oral mucositis” OR “oral cancer” OR “oral lichen planus” OR “recurrent aphthous stomatitis” OR “oral submucous fibrosis” OR “dental caries” OR “oral candidiasis”) AND (“anti-inflammatory” OR “antioxidant” OR “antimicrobial” OR “mechanism” OR “drug delivery systems” OR “clinical trial”). The initial broad search yielded more than 1,200 records.

Studies were selected for inclusion based on their relevance to the molecular mechanisms, therapeutic applications, and delivery formulations of curcumin in the context of oral diseases. The inclusion criteria were original research articles (including in vitro, in vivo, and clinical studies), high-quality systematic reviews, and meta-analyses published in English. The exclusion criteria were non-peer-reviewed publications, conference abstracts without full data, studies not focused on oral health applications, and articles for which the full text was unavailable.

The selection process involved a preliminary screening of titles and abstracts to remove duplicates and obviously irrelevant reports. The full texts of the remaining articles were then critically assessed for eligibility. The reference lists of key publications were also manually searched to identify any additional relevant studies that may have been missed in the database search. This process culminated in the inclusion of approximately 180 publications that formed the evidence base for this comprehensive review. Data from these studies were synthesized narratively to highlight the mechanisms, efficacy, and future directions of curcumin in oral medicine.

Chronic inflammation is common in periodontal disease, pulpitis, oral mucosal lesions, and even oral carcinogenesis. Curcumin’s anti-inflammatory effect is among its most potent actions and is mediated by the inhibition of pivotal signaling pathways such as nuclear factor kappa B (NF-κB). NF-κB is a transcription factor that controls the expression of numerous proinflammatory genes (the cytokines IL-1β, IL-6, and TNF-α; the enzymes COX-2 and iNOS; and adhesion molecules). Curcumin can block the activation of NF-κB by preventing the phosphorylation and degradation of its inhibitor IκB kinase (IKK) (Burge et al., 2019). In cultured cells, curcumin has been shown to inhibit cytokine-induced NF-κB activation at multiple steps, blocking IκBα degradation, nuclear translocation of NF-κB (p65/RelA), and NF-κB DNA binding, ultimately reducing downstream expression of inflammatory mediators such as interleukins and chemokines (Peng et al., 2021). By targeting an upstream signaling event (possibly at the level of NF-κB-inducing kinase), curcumin prevents the cascade that leads to NF-κB-driven gene expression (Moon, 2024). Notably, this effect has been observed across various cell types and experimental models, indicating a fundamental mechanism through which curcumin exerts anti-inflammatory activity. Core mechanisms—immunomodulation (NF-κB/COX-2 and downstream cytokines), antioxidant defense (Nrf2/HO-1 and redox homeostasis), and antimicrobial/anti-biofilm actions (including photodynamic synergy)—are active across multiple oral conditions. To minimize repetition, subsequent disease sections reference this overview and focus on clinical impact and disease-specific nuances.

Preclinical and translational data indicate that curcumin dampens NF-κB–driven cytokine cascades and actively reprograms myeloid responses in oral tissues. Chemically modified curcumin (CMC2.24) promoted M2 macrophage polarization and resolved inflammatory signaling in a diabetes-induced periodontitis model, supporting a host-modulation mechanism relevant to periodontal disease management (Deng et al., 2023). In hypercholesterolemic rats with periodontitis, systemic curcumin mitigated bone resorption and collagen degradation, which is consistent with its anti-inflammatory and osteoprotective effects (Antona et al., 2025).

In parallel, curcumin suppresses other proinflammatory pathways. It downregulates the expression or activity of enzymes such as cyclooxygenase-2 (COX-2) and lipoxygenases, thereby reducing prostaglandin and leukotriene synthesis (Nasry et al., 2018). Curcumin also inhibits the production of inflammatory cytokines (e.g., IL-6, IL-8, TNF-α) and acute-phase reactants like C-reactive protein. For example, in human gingival cells stimulated with bacterial endotoxins, curcumin significantly reduced levels of IL-6 and IL-8. This cytokine suppression contributes to curcumin’s ability to resolve inflammation in periodontal tissues and oral mucosa. Moreover, curcumin interferes with signaling cascades such as mitogen-activated protein kinases (MAPKs) and AP-1, and it can activate peroxisome proliferator-activated receptor-gamma (PPAR-γ), all of which further skew cells toward an anti-inflammatory phenotype (Davoodvandi et al., 2021).

In addition to dampening proinflammatory signals, curcumin modulates the immune response; it reduces the infiltration of neutrophils and macrophages in inflamed tissues and inhibits the release of histamine from mast cells. Curcumin can promote a shift from a pro-inflammatory M1 macrophage phenotype to a reparative M2 phenotype, aiding in tissue healing (Abdollahi et al., 2023). In T lymphocytes, compared with Th1/Th17 cytokines, curcumin tends to promote the production of Th2 and T-reg cytokines, thereby mitigating cell-mediated tissue damage. In models of oral mucosal inflammation, curcumin increased the levels of anti-inflammatory IL-10 while reducing the levels of IL-2 and interferon-gamma (Mohammadi et al., 2019). Additionally, curcumin inhibits the expression of transforming growth factor-beta (TGF-β) in patients with fibrotic oral diseases. TGF-β drives fibroblast activation and collagen deposition; by blocking TGF-β and related fibrogenic factors (e.g., connective tissue growth factor, and even pathological p53 and iNOS in precancerous fibrosis), curcumin can reduce pathological scarring in conditions such as oral submucous fibrosis (Ashrafizadeh et al., 2024). Context and dose matter: Reports of M2-like polarization with curcumin are model- and formulation-dependent. Responses vary with concentration and exposure time (biphasic effects are described in some settings), the proinflammatory stimulus (e.g., LPS vs. cytokine cocktail), cell source (primary vs. immortalized), and the delivery system (native curcumin vs. analogs/nanocarriers). Several studies have shown partial or mixed phenotypes rather than a uniform M2 shift. We therefore qualify macrophage-phenotype claims and emphasize standardized dosing and phenotyping in primary human cells and in vivo models. Assay-dependent variability: Nrf2 activation, ROS scavenging, antibiofilm effects, and aPDT activity are concentration-, time-, and context-dependent. At higher concentrations, pro-oxidant or cytostatic effects can occur; aPDT efficacy depends on the photosensitizer concentration and light parameters; and antibiofilm activity varies with species consortia and biofilm maturity.

At higher concentrations, curcumin also induces apoptosis in activated immune and inflammatory cells, which can help terminate chronic inflammation. It upregulates pro-apoptotic factors (e.g., Bax) and downregulates survival signals (e.g., Bcl-2 and survivin) in these cells, leading to programmed cell death of hyperactivated lymphocytes or aberrant oral keratinocytes. This is relevant not only for inflammatory control but also for anticancer effects. Curcumin’s ability to inhibit angiogenesis via factors such as vascular endothelial growth factor (VEGF) is another aspect of its anti-inflammatory and anticancer effects. By blocking new blood vessel formation, curcumin can deprive chronic inflammatory tissue or tumors of nutrients, thereby aiding in resolution (Peng et al., 2021). The major immunomodulatory and anti-inflammatory mechanisms of curcumin are summarized in Figure 2. Evidence basis: Conceptual synthesis (hypothesis-generating); summarizes mechanisms proposed across sources without pooled quantitative validation. This schematic highlights how curcumin disrupts key inflammatory cascades such as the IKK/NF-κB pathway, shifts immune cell phenotypes toward anti-inflammatory states, suppresses the expression of pro-fibrotic factors such as TGF-β and CTGF, and promotes the apoptosis of inflammatory cells. These actions underlie the therapeutic effects of curcumin across a range of oral diseases characterized by chronic inflammation and immune dysregulation.

Oxidativestress–an imbalance between reactive oxygen species (ROS) production and antioxidant defenses–is implicated in oral pathologies ranging from periodontal tissue destruction to mucosal inflammatory lesions and oral carcinogenesis. Curcumin has well-documented antioxidant capabilities, both as a direct free radical scavenger and as an inducer of the body’s antioxidant defense systems (Shahcheraghi et al., 2021). The chemical structure of curcumin (with phenolic OH groups and β-diketone moiety) allows it to directly neutralize ROS such as hydroxyl radicals, superoxide anions, and peroxyl radicals. By donating electrons or hydrogen atoms, curcumin can terminate free radical chain reactions, thus protecting cellular lipids, proteins, and DNA from oxidative damage (Cui et al., 2025).

Across oral and periodontal models, curcumin activates cytoprotective antioxidant pathways (e.g., Nrf2/HO-1) and restores redox balance, limiting downstream tissue injury. In ligature-induced periodontitis, curcumin reversed ferroptosis-linked lipid peroxidation by upregulating SLC7A11/GPX4 and reducing ACSL4/TfR1, thereby preserving gingival antioxidant capacity and attenuating alveolar bone damage (Wang et al., 2023).

In addition to this direct scavenging, curcumin upregulates endogenous antioxidant enzymes through the activation of the Nrf2 pathway. Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor that, upon activation, translocates to the nucleus and binds antioxidant response elements (AREs) in DNA to drive expression of antioxidant genes. Curcumin has been shown to activate Nrf2, likely by disrupting its inhibitor Keap1 or via phosphorylation events, leading to increased transcription of heme oxygenase-1 (HO-1), glutathione S-transferases, NAD(P)H: quinone oxidoreductase 1 (NQO1), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) (Dai et al., 2023; Lee et al., 2021). By promoting the release of antioxidant enzymes such as SOD, CAT, GPx, and elevating intracellular glutathione levels, curcumin enhances the cellular capacity to detoxify ROS and reactive nitrogen species. For instance, in models of oral mucositis, curcumin’s activation of Nrf2 was associated with boosted SOD and GPx activity in mucosal cells, which correlated with reduced oxidative injury and faster healing (Dipalma et al., 2024).

Curcumin also helps maintain levels of key non-enzymatic antioxidants in tissues. In patients with oral premalignant lesions (leukoplakia, submucous fibrosis), salivary and serum assays revealed that curcumin therapy significantly increased the levels of vitamins C and E, two vital antioxidant vitamins, while reducing markers of lipid peroxidation like malondialdehyde (Jiang et al., 2020). This suggests that curcumin not only provides its antioxidant effect but may also regenerate or spare other antioxidants in the body. By preventing the depletion of vitamin C and E and inhibiting the chain reactions that lead to lipid peroxidation in cell membranes, curcumin protects oral tissues from oxidative stress–induced damage. This is particularly beneficial in inflammatory environments (e.g., chronic periodontitis or lichen planus lesions) where excessive ROS from neutrophils or damaged mitochondria can perpetuate tissue injury.

An important consequence of curcumin’s antioxidant action is the interruption of oxidative stress-inflammation cycles. Oxidative stress can activate NF-κB and other inflammatory pathways, while inflammation further generates ROS–a vicious cycle in diseases like periodontal disease. Curcumin, by concurrently reducing ROS and inflammatory signals, breaks this cycle. For example, curcumin’s activation of Nrf2 leads to higher HO-1, which not only scavenges ROS but also produces anti-inflammatory molecules like bilirubin. There is cross-talk between Nrf2 and NF-κB; curcumin’s dual effect tilts the balance toward an anti-inflammatory, antioxidant state (Cui et al., 2025). This has implications for cancer prevention as well: chronic oxidative stress and inflammation create a milieu for DNA damage and mutations. By reducing both, curcumin can help prevent the initiation and progression of oral cancer. Studies in oral cancer models showed that inhibiting Nrf2 worsens oxidative damage and inflammation, whereas curcumin’s activation of Nrf2, alongside NF-κB inhibition, lowers mutagenesis and tumor growth (Huang and Pan, 2020).

Overall, curcumin serves as an antioxidant guardian in the oral cavity–neutralizing existing free radicals, upregulating protective antioxidant proteins, and thereby preserving cellular integrity. These properties underlie its efficacy in mitigating tissue destruction in periodontal disease, reducing oral mucosal erythema and ulceration, and protecting against the carcinogenic progression of precancerous lesions by preventing oxidative DNA damage. The mechanistic pathway of curcumin’s antioxidant effects is visually summarized in Figure 3. This diagram highlights how curcumin not only neutralizes ROS through direct scavenging but also enhances endogenous antioxidant defenses via Nrf2 activation. These dual actions contribute to the suppression of oxidative injury and support oral tissue resilience under inflammatory or carcinogenic stress.

Curcumin exhibits a broad spectrum of antimicrobial activity that is highly relevant to oral health, given that oral diseases are often polymicrobial. It has demonstrated inhibitory effects against Gram-positive bacteria, Gram-negative bacteria, and fungi commonly found in the oral environment (Kubizna et al., 2024; Mohammadi et al., 2019). Unlike conventional antibiotics, curcumin’s antimicrobial action is multi-modal and less prone to inducing resistance, making it an appealing adjunct or alternative, especially in an era of rising antibiotic resistance. Mechanistically, curcumin disrupts oral biofilms and enhances light-activated killing (aPDT) of key pathogens implicated in caries and periodontal disease. Randomized clinical data in orthodontic patients show that nanomicelle curcumin–mediated aPDT reduced Streptococcus mutans virulence and white-spot lesion dynamics versus controls (Nader et al., 2022). In vitro and translational work also documents curcumin-aPDT activity against Porphyromonas gingivalis biofilms and Candida spp., with emerging combinations (e.g., curcumin + chlorhexidine) potentiating antibiofilm effects (Harris and Sulewski, 2023; da Silva et al., 2025).

Periodontal diseases, including gingivitis and periodontitis, are chronic inflammatory infections of the gingiva and supporting periodontal structures caused by dental plaque biofilms. They are among the most prevalent oral diseases globally. Given curcumin’s antiplaque and anti-inflammatory actions, it has been extensively studied as an adjunct in periodontal therapy. Clinical adjunctive use is supported by randomized trials and meta-analyses. A 2025 randomized clinical study in smokers with chronic periodontitis found that adding 2% subgingival curcumin gel to SRP produced greater PPD reduction and CAL gain at 8 weeks compared with SRP alone (Gupta et al., 2025). Two recent meta-analyses concluded that local curcumin as an adjunct to SRP yields statistically significant, albeit modest, improvements in CAL and PPD compared with SRP alone and comparable outcomes to chlorhexidine adjuncts (Wendorff-Tobolla et al., 2023b).

Most periodontal RCTs are single-center with modest sample sizes and short follow-up (often ≤8–12 weeks), and formulations/doses vary across studies. Current evidence supports curcumin primarily as a therapeutic adjunct to scaling and root planing (SRP) rather than as stand-alone prevention. Data for primary prevention of periodontitis (beyond routine oral hygiene) are limited, and long-term maintenance benefits remain unproven.

Dental caries (tooth decay) is initiated by acidogenic bacteria (notably Streptococcus mutans and Lactobacilli) that demineralize enamel. Curcumin’s antimicrobial and anti-biofilm effects lend themselves to caries prevention strategies. While fluoride remains the cornerstone of caries prevention, curcumin is being explored as a complementary agent in anticaries varnishes, fillings, and dental materials.

In vitro, curcumin potently inhibits S. mutans growth and blocks its biofilm formation on tooth-mimicking surfaces (Dai et al., 2022). As mentioned earlier, curcumin interferes with S. mutans enzymes (sortase, glucosyltransferases) necessary for plaque formation. One study (Dai et al., 2022) found that a curcumin-containing resin composite applied to tooth surfaces released curcumin, which significantly reduced S. mutans colonization and lactic acid production, compared to a control composite (Inchingolo et al., 2024). This suggests that incorporating curcumin into fissure sealants or restorative materials could impart antibacterial properties and protect adjacent enamel from secondary caries. Indeed, an innovative bio-nanocomposite of carboxymethyl starch-chitosan loaded with curcumin achieved a 91% curcumin entrapment and slow release, effectively inhibiting S. mutans and preventing biofilm formation over time. Such materials may act as drug delivery systems to high-risk sites (pits, fissures, margins of restorations) to continuously exert anticaries effects. These findings are preclinical (in vitro/materials science) and demonstrate feasibility rather than clinical effectiveness; no randomized clinical trials have yet shown caries-preventive benefit for curcumin-eluting dental materials.

Curcumin has also been tested as part of herbal mouthwashes or toothpastes for caries control. A study on a curcumin-based toothpaste found that when used by children over 6 months, it significantly lowered salivary S. mutans counts and reduced new carious lesion development, performing on par with a fluoride toothpaste (Inchingolo et al., 2024). The antimicrobial action of curcumin in the toothpaste was credited with these outcomes. Some commercially available natural toothpaste brands now include curcumin (often labeled as “turmeric extract”) for its purported plaque and caries-fighting abilities. These findings are preclinical (in vitro/materials science) and demonstrate feasibility rather than clinical effectiveness; no randomized clinical trials have yet shown caries-preventive benefit for curcumin-eluting dental materials. Clinical evidence for toothpaste/mouthwash formulations remains limited by small samples and short follow-up, and curcumin products should be positioned as adjuncts—not replacements—for fluoride-based prevention.

In the realm of endodontics (root canal therapy), curcumin’s antimicrobial effect has been harnessed for disinfection of infected root canals. Enterococcus faecalis is a resilient bacterium often found in persistent endodontic infections. Curcumin, especially in combination with light activation (antimicrobial photodynamic therapy), has reduced E. faecalis biofilms within root canals in vitro and ex vivo (Narayanan et al., 2020). Curcumin can be used as an irrigant solution or canal medicament; when activated with a blue light laser, it produces reactive oxygen that kills bacteria within dentinal tubules. Studies have found curcumin-PDT to be comparable to sodium hypochlorite in several ex vivo models in reducing bacterial load, but head-to-head clinical trials versus standard irrigants are lacking, and PDT protocols (photosensitizer concentration, light wavelength/fluence) vary across studies.

Another caries-related application is curcumin’s use in pit and fissure sealants combined with photoactivation (Chaturvedi, 2009). Researchers have experimented with curcumin as a photosensitizer in sealing deep pits on teeth, where shining curing light with curcumin yields a dual effect: polymerizing the sealant and simultaneously killing any residual bacteria in the fissure. This could improve the success of sealants in arresting early pit lesions. This is a proof-of-concept methodology; clinical outcomes (caries arrest/incidence) have not yet been established in randomized trials.

Moreover, curcumin’s anti-inflammatory property might be beneficial in deep carious lesions approaching the pulp (Birjandi and Sharpe, 2025). A curcumin-based lining material placed under a filling in a deep cavity could help reduce pulpal inflammation and promote healing (via curcumin-induced odontoblast-like cell stimulation, as some in vitro studies on dental pulp cells suggest). Curcumin has been noted to induce mineralization activity in stem cells of the dental pulp (Yang et al., 2023), hinting at a role in regenerative endodontics, although this is an emerging area. These signals derive primarily from cell and animal models; clinical efficacy and safety for pulpal therapy remain to be confirmed.

In summary, while fluoride and mechanical plaque control remain primary for caries management, curcumin offers an adjunctive tool. Preclinical innovations (material elution systems, anti-biofilm/PDT effects) show feasibility, whereas clinical applications (toothpaste/mouthwash adjuncts; endodontic disinfection) are promising but require larger, well-controlled trials to confirm efficacy and define protocols.

Recurrent aphthous stomatitis (aphthous ulcers or “canker sores”) is a common oral mucosal condition characterized by painful, recurring ulcers on the non-keratinized oral mucosa. The exact etiology is unclear but involves local trauma, immune dysregulation, and possibly oxidative stress. Conventional management often uses topical corticosteroids (like triamcinolone acetonide) to reduce ulcer inflammation and pain. Curcumin, with its anti-inflammatory and wound-healing properties, has been investigated as a therapeutic option for RAS.

A growing body of evidence indicates that curcumin is effective in reducing the severity and accelerating the healing of aphthous ulcers. A systematic review of nine clinical trials with 469 patients found that curcumin significantly reduced ulcer size, pain intensity, and sometimes the number of ulcers, especially when applied as a gel, paste, or mouthrinse (Al-Maweri et al., 2022). In a double-blind randomized clinical trial, a 2% curcumin oral gel led to significant reductions in pain (often pain-free by day 3–4) and ulcer size compared to placebo (Deshmukh and Bagewadi, 2014). Similarly, a randomized trial comparing curcumin gel to triamcinolone gel found both produced comparable improvements by day 7, but curcumin avoided steroid-related side effects (Raman et al., 2020).

In head-to-head clinical comparisons, topical curcumin has demonstrated non-inferiority to standard therapy. Four trials directly compared topical curcumin with triamcinolone acetonide, showing that curcumin achieved similar improvements in ulcer healing time and pain relief (Gharibpour et al., 2021). One randomized study of 45 patients found average healing time to be ∼5 days in both curcumin and triamcinolone groups, which was faster than ∼7 days in the control group (Bakhshi et al., 2022). Pain scores measured by the visual analog scale also decreased significantly within 48 h of curcumin use.

Mechanistically, curcumin reduces local inflammation, oxidative stress, and immune dysregulation around ulcers. Biopsies from curcumin-treated ulcers revealed reduced pro-inflammatory cytokines and lower inflammatory cell infiltration compared to untreated controls (Al-Maweri et al., 2022). Curcumin also promotes re-epithelialization, facilitating faster ulcer closure. Evidence suggests that curcumin may downregulate T-cell activation implicated in RAS pathogenesis.

Some studies have reported that regular curcumin use may reduce recurrence frequency. Patients with chronic RAS who used curcumin gels during flare-ups experienced longer ulcer-free intervals during follow-up compared to previous patterns (Gharibpour et al., 2021). This may be due to curcumin’s immunomodulatory effects, which maintain a more quiescent oral mucosal environment.

Curcumin’s excellent safety profile makes it suitable for long-term or recurrent use-unlike steroids, which can cause mucosal thinning or oral candidiasis. Curcumin is well-tolerated, non-toxic, and lacks the stinging taste of antiseptics such as chlorhexidine. This makes it especially appealing for children and steroid-intolerant individuals.

Formulations include turmeric-based mouthrinses, curcumin orabase, and adhesive patches. In a randomized trial (Deshmukh and Bagewadi, 2014), a 5% curcumin orabase performed comparably to 0.1% triamcinolone, significantly reducing pain and lesion size within 5 days. Emerging technologies like curcumin-loaded oral patches have shown enhanced healing due to sustained release and localized protection.

Most RAS trials are small or pilot studies with short follow-up; histopathological validation is not applicable, and long-term safety or relapse-prevention data are limited.

In summary, curcumin represents a promising non-steroidal treatment for RAS. Clinical trials consistently show that curcumin reduces ulcer size, pain, and healing time with outcomes comparable to corticosteroids (Al-Maweri et al., 2022; Deshmukh and Bagewadi, 2014). Its excellent safety and tolerability make it ideal for long-term management, especially in patients with frequent recurrences or corticosteroid contraindications.

Oral lichen planus is a chronic immune-mediated mucosal condition, often considered a premalignant disorder, characterized by T-cell-mediated damage to basal keratinocytes and presenting with white striations, erythema, and ulcerations on the oral mucosa (Shi et al., 2024). Patients suffer from pain and burning, especially in erosive OLP. First-line therapy is usually potent topical corticosteroids or calcineurin inhibitors to control inflammation. Curcumin’s anti-inflammatory and immunomodulatory effects have made it an interesting candidate for OLP management, and several trials have explored its use either topically or systemically.

The evidence for curcumin in OLP is mixed, with some studies reporting significant improvements and others finding no difference versus placebo or standard treatment. For instance, a 2012 randomized controlled trial comparing 1% topical curcumin gel with triamcinolone in 50 OLP patients found significant reductions in pain and lesion size in both groups, with no significant differences between them (Mansourian et al., 2017). Similarly, Chainani-Wu et al. (2007) conducted a pilot trial using high-dose systemic curcumin (6,000 mg/day orally for 3 months) and observed marked reductions in symptom severity in the majority of patients, suggesting systemic curcumin could be beneficial for more extensive lesions.

However, recent systematic reviews have provided more nuanced perspectives. A 2020 review concluded that although curcumin reduced inflammatory cytokines and improved some clinical parameters, overall outcomes such as lesion erythema, pain, and ulcer size were not significantly different from placebo or corticosteroids (Lu et al., 2018). A 2024 meta-analysis supported this, noting significant heterogeneity among studies and variable efficacy depending on treatment duration and formulation (Shi et al., 2024). For example, short-duration (2-week) curcumin trials showed better results in pain reduction, while longer trials often found no differences between curcumin and placebo (Gupta et al., 2017).

Nonetheless, curcumin has shown non-inferiority in multiple head-to-head trials. In one split-mouth study, curcumin and triamcinolone both led to comparable improvements in lesion size and pain when applied to opposing sides of the mouth (Kia et al., 2020). In another placebo-controlled trial with systemic curcumin (2 g/day), improvement was observed in both curcumin and placebo groups, indicating either a placebo effect or insufficient dosing of curcumin (Kia et al., 2020).

Mechanistically, curcumin may reduce pathogenic immune activity in OLP through downregulation of NF-κB and cytokines such as IL-6, IL-8, and TNF-α, as shown in biopsy-based studies (Zeng et al., 2022). Histological changes such as reduced basal layer liquefactive degeneration and thinning of the lymphocytic band have also been observed following curcumin treatment (Gupta et al., 2017). Additionally, curcumin may promote apoptosis of hyperactive T cells in OLP lesions, contributing to lesion resolution.

Recent interest has focused on combination strategies. A 2021 trial using nanocurcumin gel plus 0.1% triamcinolone rinse showed that this combination enhanced mucosal healing compared to steroid alone, suggesting curcumin may act as a steroid-sparing agent (Kozuch and Hanauer, 2008). Nanocurcumin offers better mucosal penetration, which could explain the improved outcomes.

Sample sizes are modest and risk-of-bias elements vary; where biopsies were not repeated, histopathological confirmation of response is lacking, and long-term safety/durability remains insufficiently characterized.

In summary, curcumin shows promise for OLP management, particularly in mild-to-moderate cases or as an adjunct to reduce reliance on steroids. Its excellent safety profile, absence of mucosal atrophy, and tolerability support its continued investigation. While high-quality RCTs are still needed, clinicians may consider trialing 2%–3% topical curcumin (three to four times/day) in patients refractory to or intolerant of conventional therapy, with realistic expectations regarding variability in patient response.

Oral submucous fibrosis (OSF) is a chronic, progressive fibrotic condition of the oral mucosa strongly associated with areca nut chewing. It is characterized by inflammation and excessive collagen deposition in the submucosa, leading to stiffening of tissues, trismus (limited mouth opening), burning sensation, and a risk of malignant transformation to oral cancer. Oral leukoplakia is a white precancerous lesion often linked to tobacco use. Both conditions involve oxidative stress and a field of molecular changes predisposing to cancer. Curcumin’s anti-inflammatory and antioxidant effects, as well as its ability to modulate fibrosis pathways, make it a logical therapeutic candidate in these potentially malignant disorders.

Oral candidiasis, commonly caused by Candida albicans, is an opportunistic fungal infection of the oral mucosa. It frequently affects infants, denture wearers, or individuals who are immunocompromised or using corticosteroids. Symptoms include white plaques, redness, soreness,or burning of the mucosa. Standard treatment uses topical or systemic antifungals (nystatin, clotrimazole, fluconazole).

Curcumin’s antifungal activity has prompted research into its use for oral candidiasis, particularly given the rise of antifungal resistance and the need for alternative therapies. Preclinical research has clearly shown that curcumin is active against Candida species, including C. albicans and C. glabrata. In vitro, curcumin inhibits the growth of C. albicans at low concentrations and can kill the yeast cells at slightly higher concentrations. Notably, curcumin had inhibitory effects on C. albicans strains that were resistant to nystatin and fluconazole, with MIC values in the range of ∼8–32 μg/mL (Kubizna et al., 2024). The mechanisms include disrupting fungal cell membranes, generating intracellular ROS, and inhibiting the yeast-to-hyphae transition (Al-Ghamdi et al., 2023).

Clinically, curcumin has been applied in a few pilot studies for oral candidiasis, often in the form of mouthwash or gel. In denture-related stomatitis, patients using turmeric mouthrinse or curcumin gel experienced reduced mucosal inflammation and lower Candida counts on denture surfaces. In a randomized trial, curcumin mouthrinse performed comparably to chlorhexidine in reducing Candida colony counts, but with fewer side effects (Labban et al., 2021).

A breakthrough came with the use of curcumin-mediated photodynamic therapy (PDT) for oral thrush. Curcumin acts as a photosensitizer, producing ROS upon light activation that damages fungal cells. In a mouse model of oral candidiasis, curcumin-PDT significantly reduced fungal load and inflammation, comparable to nystatin treatment (Sakima et al., 2075). Human studies have also demonstrated PDT efficacy in resistant oropharyngeal candidiasis, especially in HIV-positive individuals (Shahi Ardakani et al., 2024).

For denture disinfection, curcumin has been evaluated in soaking solutions, showing a reduction in multispecies biofilms and fungal burden on acrylic surfaces. Nanoparticle-encapsulated curcumin incorporated into denture liners is under investigation as a slow-release antifungal barrier (Casu et al., 2022).

In terms of patient outcomes, curcumin treatment often leads to quick symptom relief (e.g., less burning, soreness), likely due to both antifungal and anti-inflammatory effects. In angular cheilitis, topical curcumin ointment reduced fissuring and erythema within 1 week of application.

To summarize, curcumin offers a safe, effective, and well-tolerated antifungal strategy for oral candidiasis. It shows promise, especially in drug-resistant strains and when used with photodynamic therapy (Hu et al., 2023). In some cases, curcumin can even restore fluconazole susceptibility in resistant Candida strains. Further trials are needed to define optimal formulations, dosages, and long-term efficacy, but the current evidence supports its adjunctive use in oral fungal infections.

Oral mucositis is a debilitating side effect of cancer therapy, particularly in patients receiving head and neck radiation or high-dose chemotherapy (e.g., for hematologic cancers). It manifests as painful inflammation and ulceration of the oral mucosa, leading to difficulty eating, swallowing, and increased risk of infection. There is no definitive treatment, and management is mainly supportive (mouth rinses, analgesics, coating agents). Curcumin has gained attention for preventing or alleviating oral mucositis due to its anti-inflammatory and wound-healing properties, and a number of clinical studies have been conducted. Recent randomized clinical evidence demonstrates symptom and severity benefits. In a 2023 single-blind RCT in head-and-neck RT patients (n = 37 completers), both a 0.1% curcumin mouthwash and a curcumin nanocapsule reduced WHO mucositis grade and pain scores versus placebo during weeks 1–3 (Ramezani et al., 2023). Two recent meta-analyses further support reductions in incidence/severity and pain, while emphasizing heterogeneity in formulations and dosing and the need for larger trials (Wu et al., 2024; Elad et al., 2013).

Clinical trials of curcumin for oral mucositis are generally small to moderate in size, with heterogeneous dosing schedules and delivery systems. Importantly, studies distinguish prophylactic (preventive) use (initiated before or at the start of RT/CT to reduce incidence/severity) from therapeutic use (to treat established mucositis). While signals are favorable in both contexts, effect sizes differ by formulation and timing, and larger, multi-center RCTs with standardized outcomes are needed.

Oral squamous cell carcinoma (OSCC) is the most common oral malignancy, often arising from precancerous lesions or in the context of risk factors like tobacco, alcohol, or HPV infection. Treatment involves surgery, radiation, and chemotherapy, but survival rates remain modest, and new therapeutic strategies are needed. Curcumin has garnered interest in oncology due to its ability to modulate cancer cell growth and metastasis pathways, induce apoptosis, and enhance the efficacy of conventional treatments. In the context of oral cancer, curcumin has been studied in laboratory models, and early-phase clinical trials have explored its effects either as a chemopreventive or as an adjuvant to therapy. Translational data in patients suggest biological activity at the tumor–host interface. In a randomized, placebo-controlled phase-1 ‘window’ trial, a curcumin-containing botanical (APG-157) achieved measurable systemic absorption and reduced salivary pro-inflammatory cytokines (IL-1β, IL-6, IL-8) and tumor-associated microbes in OSCC patients (Basak et al., 2020). While early-phase outcomes are promising, major cancer agencies still judge evidence as insufficient for routine oncologic treatment and call for larger, well-controlled trials (PDQ Integrative et al., 2024).

At present, curcumin should be regarded as an adjunct or investigational add-on rather than a primary oncologic therapy; standard management continues to rely on surgery, radiotherapy, and systemic therapy, with curcumin explored primarily for biomarker modulation and symptom control.

In OSCC, evidence is largely preclinical or early-phase. Existing randomized ‘window’ trials are small and focus on biomarker and microbiome modulation; there is no evidence yet for survival or local control benefit. Accordingly, curcumin should not be represented as a therapeutic oncologic treatment outside clinical trials. Its potential preventive role pertains mainly to premalignant conditions (e.g., leukoplakia, oral submucous fibrosis), where symptomatic and functional improvements have been reported, but durable cancer-preventive efficacy remains uncertain.

The simplest formulation is a curcumin mouthwash. Typically, a turmeric extract or curcumin powder is dissolved or suspended in water (often with a small amount of ethanol or a solubilizing agent) to create a rinse. Patients are instructed to swish for 1–2 min to allow contact with all oral surfaces. Curcumin mouthwashes of 0.1%–1% concentration have been widely used in trials for gingivitis, mucositis, etc., with positive outcomes as discussed. The advantage of a rinse is ease of use and the ability to reach all corners of the mouth. To improve curcumin’s solubility in rinses, formulations may include adjuvants like piperine (from black pepper, which inhibits curcumin metabolism and increases uptake) or use nanomicelle technology. One study utilized a nanomicellar curcumin mouthwash (SinaCurcumin®) where curcumin is encapsulated by surfactant micelles, making it water-soluble (Inchingolo et al., 2024). This formulation significantly delayed and reduced chemotherapy-induced mucositis, with no reported difficulties in use. Nanomicelles protect curcumin from precipitation and enzymatic degradation in saliva, thereby delivering more active compound to tissues (Rezaei-Tazangi et al., 2023).

Curcumin gels (typically a hydrogel base like carbopol or xanthan gum, loaded with curcumin) are useful for adhesive application on specific lesions (e.g., aphthous ulcers, OLP patches, perioperative wounds). Gels can ensure prolonged contact time. A 2% curcumin gel has been a common choice, often applied 3–4 times daily. The gel form has shown high efficacy in conditions like oral mucositis and OLP (Pan-On et al., 2022), likely because it forms a protective layer and keeps curcumin concentrated at the lesion site. Some gels combine curcumin with other ingredients; for example, curcumin has been formulated in Orabase (an adhesive paste often used for steroid application) to treat ulcers–the orabase ensures the curcumin is not quickly washed away by saliva.

To further prolong exposure, researchers have developed curcumin mucoadhesive patches. These are small disks or strips (often made of polymers like hydroxypropyl cellulose or chitosan) that can stick to the oral mucosa and slowly release curcumin. A mucoadhesive film containing curcumin was tested for aphthous ulcers–patients applied the patch to the ulcer and left it in place, where it dissolved over ∼30 min, delivering curcumin into the ulcer site. This method was found to significantly reduce ulcer pain within hours and speed up healing, with the convenience of once or twice daily application rather than multiple gel applications (Gopalakrishna et al., 2023). Similarly, for OLP lesions on the buccal mucosa, curcumin films provided continuous drug delivery, and patients found them easy to use without interfering with speech or eating (as they adhere until dissolved).

Nanotechnology has been employed to enhance curcumin delivery. Curcumin can be encapsulated in nanoparticles (e.g., polymeric nanoparticles, solid lipid nanoparticles, or nanoemulsions) that not only improve solubility and stability but can also facilitate uptake into tissues. One example is nanocurcumin–curcumin loaded into polymer nanoparticles of ∼50–100 nm. In a trial for gingivitis, an oral nanocurcumin suspension led to greater reductions in the gingival index and bleeding on probing than a traditional curcumin prep, likely due to better penetration into the gingival crevices. Nanoparticles can also allow curcumin to penetrate biofilms more effectively, enhancing its antimicrobial action. Liposomal curcumin (curcumin enclosed in phospholipid vesicles) is another strategy; the liposomes can fuse with bacterial membranes to deliver curcumin directly where needed. Some mouthrinse formulations incorporate liposomal curcumin for improved shelf stability and mucosal absorption.

In periodontal pockets, maintaining drug presence is challenging due to saliva flow. Thus, intra-pocket devices have been crafted. These include curcumin strips or fibers that are inserted into deep pockets after SRP, where they slowly release curcumin over several days. A study designed a biodegradable film with curcumin (as mentioned earlier) and found it successfully released curcumin in a sustained manner in the pocket and improved periodontal outcomes. Chitosan, being mucoadhesive and biodegradable, is often used to make such films. A variant is curcumin in situ gels that are liquid when injected into a pocket and then solidify into a gel that adheres to the pocket walls, releasing curcumin over a week. These targeted delivery systems ensure high curcumin concentration directly at the diseased site for extended periods, which is ideal for chronic periodontitis management (Hegde et al., 2023).

Curcumin has been included in some herbal toothpastes aimed at reducing plaque and gingivitis. While the contact time during brushing is short, daily use does impart some cumulative effect. Curcumin toothpastes have shown the ability to reduce oral microbial counts and inflammatory markers in the gingival crevicular fluid. Chewing gum with curcumin is an innovative concept studied in a trial for oral cancer patients–a curcumin-infused gum was chewed to deliver curcumin to oral tissues systematically. Chewing the gum released curcumin that got absorbed through the oral mucosa and led to measurable decreases in serum inflammatory markers like CXCL1 and TNF-α. This suggests a gum could be a convenient delivery mode for curcumin as a chemopreventive in populations at risk of oral or systemic disease (Hao et al., 2025).

Combining curcumin with bioenhancers is another strategy. Piperine is most well-known; it can increase curcumin’s bioavailability by 20-fold by inhibiting glucuronidation in the liver. Some oral supplements pair curcumin with piperine for systemic absorption. For example, patients with OSF took curcumin capsules containing piperine and saw a good clinical response, presumably because enough curcumin reached the oral tissues systemically (Mohajeri et al., 2021). Other enhancers include using curcumin in oils or lipid bases (since curcumin is lipophilic). Curcumin dissolved in coconut oil or olive oil has been used as an oil-pulling or swishing therapy in anecdotal reports for oral hygiene improvement. Indeed, curcumin’s absorption is improved when taken with oils (Harwansh et al., 2023), a fact noted in traditional uses (like mixing turmeric in ghee or milk).

To address stability, some delivery forms use curcumin analogues or derivatives with better pharmacokinetics. While not exactly “curcumin,” these modified compounds (e.g., EF24, a curcumin analog) might be included in future oral care products if they prove more effective. The characteristics of major curcumin delivery systems tailored for oral application are summarized in Table 2.

Regulatory and formulation considerations—From a regulatory perspective, curcumin is not approved by the U.S. Food and Drug Administration (FDA) to treat any disease; most U.S./EU products are regulated as dietary supplements or cosmetics/oral-care preparations, not as drugs. Curcumin and turmeric oleoresin are permitted in foods (e.g., as color additives/GRAS), but these listings do not confer therapeutic approval. Several curcumin-containing oral-care gels are commercially available in India under Ayurvedic/OTC frameworks (e.g., Curenext™ curcuma oral gel), while a curcumin-containing botanical lozenge (APG-157) has shown biologic activity in a randomized Phase 1 trial in oral cancer and currently holds FDA Fast Track designation in head-and-neck cancer (Basak et al., 2020); however, no curcumin oral product is FDA-approved for disease treatment (PDQ Integrative et al., 2024). Formulation challenges that constrain translation include poor aqueous solubility, pH/photochemical instability, rapid metabolism, and short mucosal residence times. These issues motivate the use of mucoadhesive gels/films, nanomicelles/phytosomes/cyclodextrins, and photosensitizer formulations for aPDT to enhance solubility, retention, and local bioavailability. Standardization is also critical: curcuminoid composition (curcumin/demethoxycurcumin/bisdemethoxycurcumin ratios), excipient profiles, and release characteristics vary widely across products, complicating dose equivalence and trial comparability. Future development should predefine the regulatory route (drug vs. device vs. supplement), adopt quality-by-design and cGMP standards, and include stability/compatibility data and device–drug integration (for light-activated therapies) to support scalable, regulator-ready formulations.

In conclusion, significant progress has been made in developing tailored curcumin delivery systems for oral use. These range from simple mouthwashes to sophisticated nanocarriers and mucoadhesive devices. The goal is to maximize curcumin’s localized effect while minimizing the need for very high systemic doses. As research continues, we may see curcumin incorporated into everyday dental products (mouthwashes, dentifrices) and also into prescription devices for periodontal therapy or mucosal disease management. The array of formulations ensures that curcumin’s versatility can be practically harnessed in different clinical scenarios, improving patient compliance and outcomes.

At least 18 randomized controlled trials (RCTs) have evaluated curcumin as an adjunct in periodontal therapy. As summarized by a 2022 meta-analysis, these trials (totaling ∼846 patients) consistently show that adjunctive curcumin (gel, irrigation, or mouthwash) with standard scaling and root planing yields greater reductions in the gingival index, bleeding index, and pocket depth than scaling and root planing alone (Afrasiabi et al., 2022). No serious adverse effects were reported, and curcumin was often noted to improve patient-reported outcomes (less gum soreness after deep cleaning, etc.). These findings establish curcumin as an effective adjunct, on par with other adjuncts like chlorhexidine or antibiotics, but with fewer downsides (no staining or resistance issues). While most periodontal trials are short-term (4–12 weeks), a few longer studies indicate that a curcumin adjunct can sustain periodontal health over 6 months when used periodically for maintenance. Ongoing studies are looking at curcumin in peri-implantitis and aggressive periodontitis cases. Compared with chlorhexidine (CHX) adjuncts to scaling and root planing (SRP), local curcumin formulations typically show modest but statistically significant PPD/CAL improvements versus SRP alone, with outcomes broadly comparable to CHX in several trials (Wendorff-Tobolla et al., 2023a; Gupta et al., 2025; Zhang et al., 2021). Mechanistically, CHX acts via rapid bactericidal membrane disruption, whereas curcumin combines anti-biofilm/quorum-sensing interference, host-directed NF-κB/COX-2 attenuation, and, when used as a photosensitizer, reactive-oxygen generation (aPDT) (Lee et al., 2021). Curcumin is associated with fewer reports of tooth staining or taste disturbance than CHX, though high-quality comparative safety data are limited (Bossi et al., 2024); formulation heterogeneity and short follow-up warrant caution, and curcumin should be positioned as an investigational adjunct, not a replacement for CHX-based care (Zhang et al., 2021).

Over a dozen RCTs and several systematic reviews have examined curcumin for mucositis in cancer patients. A recent 2025 systematic review identified 12 trials (in patients undergoing radiotherapy/chemotherapy) and concluded that curcumin significantly reduces the risk, onset, and severity of oral mucositis across different cancer treatment regimens (Hao et al., 2025). For example, in head and neck cancer radiotherapy, meta-analyses show curcumin users are ∼50% less likely to develop severe mucositis (Grade 3–4) compared to controls (Zhang et al., 2021). In bone marrow transplant patients, curcumin mouthwash shortened mucositis duration by about 4–5 days on average versus placebo. These trials uniformly report improved oral pain scores and nutritional intake in curcumin groups (Bossi et al., 2024). The evidence here is strong enough that curcumin mouthwash is being incorporated into some standard care protocols for mucositis prevention. The trials also underscore curcumin’s safety: even in immunocompromised populations, curcumin did not predispose to infection or interfere with cancer therapy. Guideline-endorsed supportive options include benzydamine mouthwash and photobiomodulation alongside oral-care protocols (Elad et al., 2020). Curcumin (mouthwash/gel/nanocapsules) has reduced WHO grade and pain in randomized studies, but effect sizes vary with formulation and timing (Zanatta et al., 2010). Clinically, curcumin should be considered an adjunct within supportive-care pathways rather than a standalone therapy.

Nine trials (469 patients) were summarized in a 2021 systematic review. The pooled data show curcumin treatment leads to faster healing of aphthous ulcers and greater pain reduction compared to placebo or no treatment, with results comparable to topical steroids in head-to-head comparisons (Al-Maweri et al., 2022). Approximately 70%–85% of patients receiving curcumin had significant improvement in pain within 3–4 days, versus 30%–40% of controls (Bakhshi et al., 2022). Ulcer size reduction was likewise more pronounced. There is moderate-quality evidence supporting curcumin as a first-line or adjunctive therapy in RAS, especially for patients with frequent or multiple ulcers. However, heterogeneity in formulations (rinses vs. gels) and treatment durations means future trials should standardize these parameters to strengthen recommendations (Deshmukh and Bagewadi, 2014).

Clinical trials for OLP have yielded mixed results, as discussed. A 2024 meta-analysis of 10 studies found no overall significant benefit (Singh et al., 2023), while some individual RCTs did show that curcumin equals steroids in efficacy. The evidence quality is moderate to low, partly due to small sample sizes (most OLP trials have 20–40 patients per arm) and variations in outcome measures. Nonetheless, given curcumin’s safety and some positive signals, it is often considered a second-line option. Larger, multicenter trials are needed for OLP to reach a more definitive conclusion. At least one such trial is ongoing (testing nanocurcumin gel versus corticosteroid in erosive OLP with ∼100 patients). Standard care relies on topical corticosteroids (and calcineurin inhibitors in select cases). Curcumin has shown symptom relief and potential steroid-sparing effects in small trials; adequately powered, dose-standardized comparisons versus corticosteroids are needed before routine substitution (Amirchaghmaghi et al., 2016).

There have been at least 5 controlled trials in OSF and a few in leukoplakia. The aggregated evidence indicates curcumin (especially systemic plus topical) is efficacious in improving OSF symptoms and mouth opening, with several trials showing equivalence or superiority to standard treatments like intralesional steroids (Pan-On et al., 2022). One systematic review (Inchingolo et al., 2020) looking at natural antioxidants in OSF included curcumin trials and noted significant improvement in burning sensation and mouth opening in curcumin groups compared to baseline (Inchingolo et al., 2024). Curcumin also appeared to downstage the histopathological grading in some OSF cases (i.e., severe fibrosis turning to moderate). The level of evidence here is moderate; more large RCTs would bolster confidence. Given OSF’s prevalence in Southeast Asia, curcumin has been integrated into some routine management protocols there.

While not as many RCTs exist for caries, the antiplaque efficacy of curcumin mouthwash has strong evidence (multiple trials vs. chlorhexidine). For caries prevention specifically, we rely on surrogate markers (plaque reduction, S. mutans counts). These surrogate outcomes all trend positively for curcumin (Mohajeri et al., 2021). One could extrapolate that sustained plaque control via curcumin would translate to lower caries incidence, but long-term caries trials are lacking. Nevertheless, at least one 1-year study in children saw fewer new caries with curcumin toothpaste use, suggesting a real-world benefit.

Human data are early but promising. The Phase I trial of curcumin lozenges in oral cancer patients demonstrated biological activity (cytokine reduction) without toxicity, fulfilling its Phase I goals (Hegde et al., 2023). A follow-up Phase II (with curcumin + immunotherapy) will provide more insights into clinical efficacy. Additional evidence from microbiome modulation studies further suggests benefits (Gopalakrishna et al., 2023). Meanwhile, numerous in vivo studies and indirect clinical evidence (like curcumin’s effects in OSF, which is a cancer precursor) support that curcumin likely has beneficial anticancer effects. The evidence here is currently low-level in humans but high-level in mechanistic plausibility. Curcumin is investigational and not a replacement for surgery, radiotherapy, or chemotherapy. A randomized phase-1 window trial of a curcuminoid lozenge (APG-157) demonstrated salivary cytokine/microbiome modulation and systemic absorption, and the agent has received FDA Fast Track status; no survival or local-control benefit has been shown to date, so integration should occur only within clinical trials (Basak et al., 2020).

It is noteworthy that across 80–100 studies on curcumin in oral conditions, no significant adverse events have been reported attributable to curcumin. Mild events like transient tongue yellowing (from the pigment) or a slight burning sensation (rarely) have been noted, but these are negligible compared to the side effects of many standard drugs. In high-dose systemic use (e.g., 6 g/day in the OLP study), some patients reported minor gastrointestinal upset, but even that was infrequent. This excellent safety, even in vulnerable patient groups, is a critical aspect of curcumin’s clinical appeal.

In evidence hierarchy, multiple meta-analyses and systematic reviews now exist–for periodontitis, mucositis, RAS, etc., – most of which conclude that curcumin is effective and recommend its consideration in clinical practice. The strength of recommendation is strongest for conditions like gingivitis, periodontitis, and mucositis, where numerous high-quality RCTs concur on benefit. For others, like OLP and candidiasis, recommendations are cautious or suggest curcumin as an adjunct pending more data.

In summary, the accumulated clinical evidence positions curcumin as a versatile therapeutic adjunct in oral healthcare. It has been tested in a wide array of patient populations–from healthy individuals for plaque control to cancer patients for mucositis or tumor suppression–and shown beneficial outcomes with minimal risks. As research continues, we expect to see even more refined data (for example, dosage optimization, comparisons of curcumin formulations, and long-term effects). But even with current evidence, clinicians can feel reasonably confident in advising curcumin-based interventions as part of comprehensive oral disease management, aligning with patient preferences for natural remedies when appropriate.

Despite numerous delivery innovations, enhancing the bioavailability and retention of curcumin in oral tissues continues to be a priority. Future research may focus on novel curcumin analogues that retain activity but have better solubility or stability (Bapat et al., 2023). For instance, analogues such as EF-24 or THC (tetrahydrocurcumin) could be tested in oral disease models. Additionally, controlled-release systems can be further refined, such as multilayer mucoadhesive patches that provide an initial burst of curcumin for pain relief, followed by sustained release for healing. Nanoformulations using dendrimers or stimuli-responsive nanoparticles (that release curcumin in response to pH or enzymes present at disease sites) are intriguing possibilities. The goal is to ensure adequate curcumin levels at the target site for a sufficient duration, thereby maximizing efficacy.

Manycurrent clinical studies of the role of curcumin in oral health have relatively small sample sizes or single-center designs. To strengthen the evidence and potentially influence clinical guidelines, large, multicenter randomized trials are needed (Inchingolo et al., 2024; Gobbo et al., 2024). For example, a large trial in periodontal maintenance patients could compare curcumin gel vs. placebo over a year to determine differences in clinical attachment loss or tooth retention. In oral mucositis, a phase III trial of curcumin rinse vs. standard care across multiple cancer centers could pave the way for formal recommendations in oncology protocols (Morsy et al., 2023). Similarly, a sizable trial in recurrent aphthous stomatitis comparing curcumin, steroids, and placebo in a crossover design would be valuable to conclusively prove (or refute) the benefit of curcumin. Such trials should also standardize curcumin preparations (perhaps using pharmaceutical-grade bioavailable formulations) to make results generalizable.

While mechanistic insights abound from in vitro and animal studies, more translational research in humans would help clarify how curcumin works in vivo (Mukherjee and Krishnan, 2023). This could include tissue biopsies or saliva analyses from patients before and after curcumin treatment, and examination of changes in inflammatory mediators, gene expression profiles, and microbiome composition, etc. For example, analyzing gingival crevicular fluid in patients with periodontitis treated with curcumin might reveal reductions in specific cytokines or bone resorption markers (such as RANKL), solidifying the causal link between the molecular effects of curcumin and clinical improvements (Siyuan et al., 2023). In patients with OSCC taking curcumin, tumor tissue analysis could confirm the modulation of angiogenesis or immune cell infiltration as seen in preclinical models (Joshi et al., 2023). Biomarker studies such as these would bolster the mechanistic rationale for curcumin and could identify responders vs. nonresponders (perhaps some individuals have differences in curcumin metabolism or target expression that influence outcomes).

Future research should explore how curcumin can be integrated with existing treatments for synergistic effects. For example, whether the combination of curcumin with a low-dose local antibiotic in periodontitis could yield additive benefits could be explored. Alternatively, in oral cancer, combining curcumin with immunotherapy or targeted therapy might improve response rates, as suggested by early trials. Curcumin might also synergize with other natural agents–a combined oral herbal rinse [e.g., curcumin with green tea (Camellia sinensis (L.) Kuntze; family Theaceae) extract or aloe vera (L.) Burm.f. (family Asphodelaceae)] might cover a broader spectrum of activity. Curcumin as a steroid-sparing agent is another area of research, such as the use of lower doses of steroids in OLP or OSF when curcumin is concurrently administered, to evaluate whether this reduces steroid side effects while maintaining efficacy. Combination regimens need careful design, but they could maximize patient outcomes by attacking diseases on multiple fronts. Table 4 outlines recent and ongoing studies exploring the use of curcumin in combination with other therapeutic modalities for oral diseases.

Individuals may vary in their response to curcumin. Future studies might identify genetic polymorphisms that affect the metabolism of curcumin (such as in UDP-glucuronosyltransferases) or polymorphisms in inflammatory genes that make someone more or less responsive to the activity of curcumin (Kumar et al., 2022). This could pave the way for a personalized approach in which curcumin is recommended more strongly to patients who are predicted to benefit (e.g., those with high NF-κB activity profiles, or those with certain microbiome characteristics that curcumin can modulate). Tailoring treatment intensity, such as more frequent curcumin application for patients with severe oxidative stress markers, could also be explored.

More data on the long-term use of curcumin in the oral cavity are needed. Can daily use of curcumin over the years prevent dental caries or periodontal progression? Does long-term use in patients with precancerous lesions reduce malignant transformation rates? Cohort or observational studies could address these questions (Viglianisi et al., 2024). For instance, tracking a group of patients with OSF or leukoplakia on long-term curcumin supplements versus a control group could yield insights into differences in cancer incidence over time. Similarly, a community-level study in which one group used a curcumin-infused oral care regimen and the other did not will show differences in the incidence of caries or gingivitis over a few years. These studies would help position curcumin not only as a treatment but also as a preventive or maintenance agent in oral health.

Several experts have highlighted that curcumin may behave as a “Pan-Assay Interference Compound” (PAINS), raising concerns that some reported in vitro activities may reflect assay artefacts or nonspecific promiscuous binding rather than true target-specific effects (Bolz et al., 2021). This underscores the need to clearly separate in vitro findings from validated in vivo pharmacodynamics. Future research should critically evaluate whether sufficient active curcumin (or its metabolites) reaches oral or systemic target tissues at pharmacologically relevant concentrations in humans, and whether observed clinical benefits correlate with biologically plausible exposure–response relationships.

As more evidence accumulates, efforts can be made to achieve regulatory endorsements for curcumin in specific indications (e.g., FDA or EMA approvals of a curcumin oral rinse as a medical device or drug for mucositis) (Batra et al., 2019). Future work may involve creating standardized, quality-controlled curcumin products and conducting the necessary trials for approval. This will ensure wider acceptance in mainstream practice.

There are oral conditions not yet well-studied with respect to the role of curcumin. For example, could curcumin mouthwash help in halitosis by reducing oral microbial load and volatile sulfur compound production? Alternatively, in Sjogren’s syndrome, where oral dryness and inflammation are issues, curcumin might aid minor salivary gland inflammation. Orthodontic treatment pain or ulceration is another area where a curcumin gel might soothe the mouth ulcers that sometimes occur with braces (Srivastava et al., 2018). These exploratory areas could open new uses for curcumin.

In conclusion, while the use of curcumin has already transitioned from the bench to the bedside in many respects, continuing research is vital to address the remaining questions and expand its utility. An emphasis on rigorous, large-scale trials, innovative delivery, and mechanistic clarity will help integrate curcumin more fully into evidence-based oral healthcare. In the future, a scenario in which curcumin (or improved derivatives) could become a routine component of dental and oral medicine practices, as a preventive supplement, a treatment adjunct, or even part of restorative materials is likely, contributing to a more holistic and natural approach to managing oral health and disease.